BIAF prices $4.0M at-the-market private placement — 8.46M shares (or pre-funded warrants) + 2 warrants per share; closing ~Aug 14
AI Summary
BioAffinity (BIAF/BIAFW) agreed to sell 8,462,027 common shares (or pre-funded warrants in lieu) together with two warrants per share (up to 16,924,054 warrant shares) in a private placement priced at-the-market for combined effective prices of $0.4727 per share (or $0.4657 for pre-funded combos). Gross proceeds are expected to be approximately $4.0 million before fees, the offering is expected to close on or about August 14, 2026, WallachBeth is the placement agent, and the warrants will only be exercisable following stockholder approval and expire five years after issuance. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
Positives
- Warrants are not exercisable until stockholder approval, delaying additional exercisable dilution
Negatives
- 8,462,027 shares plus up to 16,924,054 warrant shares represent material potential dilution if fully issued/exercised
- Pre-funded warrants have a $0.007 exercise price, enabling near-zero-cost conversion to common shares
- Warrant coverage is 2 warrants per share purchased, creating a large contingent share overhang
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: stockholder approval
Dilution status
conditional
Dilution timing
Dilution status: Undetermined
Trigger type
shareholder_approval